BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

AUTL

Autolus Therapeutics plc
Nasdaq · Biological products, (no diagnostic substances) (SIC 2836) · FY ends 31 Dec

Revenue, quarterly

$46M+118.4% year on year
$60M$40M$20M$0
Q1 ’24Q3 ’24Q2 ’25Q4 ’25Q2 ’26
Company filings · 10-Q filed 11 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

15.7%+95.3 pp year on year
100%0%−100%−200%−300%
Q4 ’24Q2 ’25Q3 ’25Q1 ’26Q2 ’26
Company filings · 10-Q filed 11 Aug 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$171M+38.4% year on year
$1B$500M$0
Q4 ’23Q3 ’24Q1 ’25Q4 ’25Q2 ’26
Company filings · 10-Q filed 11 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$233M
$200M$0−$200M−$400M
Q4 ’24Q2 ’25Q3 ’25Q1 ’26Q2 ’26
Company filings · 10-Q filed 11 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty